ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

ClinicalTrials.gov ID: NCT00105183

Public ClinicalTrials.gov record NCT00105183. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-human-T-lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s)

Study identification

NCT ID
NCT00105183
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Neovii Biotech
Industry
Enrollment
223 participants

Conditions and interventions

Interventions

  • EZ-2053 Biological
  • EZ-2053 5mg/kg Biological
  • Placebo Biological

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2004
Primary completion
Dec 31, 2009
Completion
Dec 31, 2010
Last update posted
Jun 10, 2012

2005 – 2011

United States locations

U.S. sites
15
U.S. states
11
U.S. cities
14
Facility City State ZIP Site status
Cedars-Sinai Medical Center Los Angeles California 90048
University of California, San Francisco San Francisco California 94143
Stanford University Stanford California 94305
Mayo Clinic Jacksonville Florida 32224
Emory University School of Medicine Atlanta Georgia 30322
University of Iowa Hospital & Clinics Iowa City Iowa 52242
University of Kentucky Medical Center Lexington Kentucky 40536
Barnes-Jewish Hospital St Louis Missouri 63110
Cleveland Clinic Cleveland Ohio 44195
INTEGRIS Baptist Medical Center Oklahoma City Oklahoma 73112
University of Pennsylvania Medical Center Philadelphia Pennsylvania 19104
Temple University Hospital Philadelphia Pennsylvania 19140
Vanderbilt University Nashville Tennessee 37232
Baylor College of Medicine Houston Texas 77030
University of Texas Health Sciences Center San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00105183, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 10, 2012 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00105183 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →